Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mw Immunomodulation in Severe Sepsis
NCT02025660Phase 3Completed
- Sponsor
- Post Graduate Institute of Medical Education and Research
- Start
- Aug 2013
- Primary completion
- Feb 2014
- Modality
- Prophylactic Vaccines, Microbiome Therapeutics, Therapeutic Vaccines
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of MYCIDAC-C in sepsis and septic shock (2 arms), sponsored by Post Graduate Institute of Medical Education and Research. Primary endpoint: Mortality at 4 weeks. Started Aug 2013; status: completed.
02
Drugs
MYCIDAC-C
03
Conditions
sepsisseptic shock
Beyond the preview
Go deeper on NCT02025660.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02025660.